Biomedtech News

Abivax selected for a presentation at the 40th Annual J.P. Morgan Healthcare Conference

January 12, 2022

Abivax has been selected for a presentation at the 40th Annual J.P. Morgan Healthcare Conference.

The J.P. Morgan Annual Conference is the largest investor symposium in the healthcare industry. It will be held January 10-13, 2022.

ALSO TO BE DISCOVERED

December 2, 2021

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

December 1, 2021

Abivax's drug-candidate ABX196, shows good tolerability and promising signals of clinical benefit in liver cancer

October 19, 2021

ABX464 shows excellent long-term efficacy data in Abivax's phase 2B maintenance trial in ulcerative colitis

September 24, 2021

Abivax presents first-half 2021 financial results and operations update

September 15, 2021

Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis

September 8, 2021

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

September 8, 2021

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck

August 23, 2021

Could HIV be cured by tackling ‘bumpy’ CD4 cells? France’s Diaccurate wants to find out

August 18, 2021

Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis

July 19, 2021

Carmat sells its artificial heart for the first time in Italy